QIAGEN powered by

QCI Interpret™

Whether you’re assessing a patient’s risk of hereditary cancer or interpreting genomic data to identify potential therapies and clinical trials for a cancer patient, QIAGEN Clinical Insight Interpret software delivers the highest quantity and quality of clinical evidence to improve patient care.




Confidently report results quickly to clinicians

Automated interpretation enables efficient review, sign-off and rapid report delivery.


Standardized interpretation and reporting

Integrated with ACMG/AMP guidelines for hereditary disease assessment and AMP/ASCO/CAP guidelines for somatic testing enabling universal and clear communication within the medical community.


Full transparency of clinical evidence

Assess clinical actionability and pathogenicity with visibility to each piece of evidence linked to the quality-assured, source publication.



Clinical evidence at your fingertips

Access the industry’s largest, most up-to-date knowledgebase with nearly two decades of curation maintained in real-time by hundreds of MDs and PhDs.


Supporting services to help you launch or expand your NGS testing program

Our team of experts are available to help effectively mange your NGS workflow, from planning to implementation.


Industrial-strength data protection

We understand your data is precious; we provide peace of mind with comprehensive security combining network security, and system and software integrity.


> Clinical evidence at the touch of a button




Improved clinical
decisions for cancer patients

Treatment and care decisions for cancer patients require extensive clinically-relevant information. QCI Interpret is continuously updated to provide the most current information to improve accuracy in NGS test interpretation and reporting.


As an undisputed industry leader and pioneer of molecular technologies, we combine decades of experience and global expertise to improve patient care for generations to come.


Clinical labs rolling out NGS-based cancer tests are confronted with two key challenges: the complexity of turning molecular profiling information into precise medical recommendations, and the time and effort it takes to generate actionable reports. QIAGEN Clinical Insight provides a rich and detailed, yet very clear and concise, report that suggests management and treatment options based on the patient’s gene variations that profile their disease and outline causal links. It is this kind of interpretation that gives clinical value to the data, and what enables the actual insights into a patient’s specific disease and treatment options.


Madhuri Hegde, PhD, FACMG

Professor of Human Genetics at the Emory University School of Medicine and Executive Director of the Emory Genetics Laboratory